Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in Austria.
Ronceray L, Dworzak M, Dieckmann K, Ebetsberger-Dachs G, Glogova E, Haas OA, Jones N, Nebral K, Moser R, Lion T, Meister B, Panzer-Grümayer R, Strehl S, Peters C, Pötschger U, Urban C, Mann G, Attarbaschi A; Austrian Berlin-Frankfurt-Münster (BFM) Study Group.
Ronceray L, et al. Among authors: meister b.
Wien Klin Wochenschr. 2023 Aug 3. doi: 10.1007/s00508-023-02249-6. Online ahead of print.
Wien Klin Wochenschr. 2023.
PMID: 37535134